Aardvark Therapeutics (AARD) Free Cash Flow (2024 - 2026)
Aardvark Therapeutics (AARD) posted Free Cash Flow of -$18.9 million for Q1 2026, down 12.25% sequentially from -$16.8 million in Q4 2025, and down 65.69% YoY from -$55.0 million in Q1 2025.
Aardvark Therapeutics (AARD) Free Cash Flow (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Free Cash Flow for 3 years, with the latest figure at -$18.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 65.69% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.7 million (down 125.45% YoY) and the FY2025 annual result came in at -$54.3 million, down 198.24% from the prior year.
- Free Cash Flow declined to -$18.9 million in Q1 2026 per AARD's latest filing, from -$16.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.2 million in Q1 2024 and troughed at -$18.9 million in Q1 2026.
- A 3-year average of -$10.1 million and a median of -$9.9 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow tumbled 418.82% in 2025, then slumped 65.69% in 2026.
- Over 3 years, Free Cash Flow stood at -$7.7 million in 2024, then plunged by 117.38% to -$16.8 million in 2025, then dropped by 12.25% to -$18.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$18.9 million, -$16.8 million, and -$16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | -17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.60 Mn |
| Jun 30, 2026 | -17.60 Mn |
| Mar 31, 2026 | -18.87 Mn |
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Jun 30, 2025 | -9.94 Mn |
| Jun 30, 2025 | -9.94 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -4.31 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |